Thank you for attending SCLC 2021. Registration and access to the sessions are available through January 30, 2022 at 15:00 EST. To collect a certificate of attendance please email meetings@iaslc.org. If you have already registered for the program and would like to access the meeting content, please access the platform at the link below.
Overview
The fourth biennial IASLC Small Cell Lung Cancer Meeting will be held as a Worldwide Virtual Event in the Fall of 2021. The meeting will focus on preclinical and clinical advances in small cell lung cancer (SCLC) research, including, but not limited to, basic research on oncogenesis and biology of disease, preclinical therapeutic research, and highlights of ongoing clinical translation. From its inception, this meeting's goals have been to provide a “state-of-the-state” update on recent progress in small cell lung cancer research, to establish a forward-looking perspective on key unanswered questions in the field, and to promote research collaboration among small cell lung cancer investigators. We hope that you will join us for #SCLC21. Additional meeting information will follow soon.
Related Files
Detailed Program
Thursday, October 28, 2021
CURE® is proud to host the second annual Lung Cancer Heroes® recognition event on Thursday, October 28, 2021 at 6:30 p.m. ET! Join us in honoring and expressing our heartfelt gratitude to this year’s honorees who have made a difference in the lung cancer community and continue to bring hope and healing to patients and their loved ones. CURE® is also pleased to announce that award-winning actress and filmmaker Laura Dern will be delivering this year’s keynote address! Please join us to make it an evening to remember.
Friday, October 29, 2021
All Times in ET
Opening Ceremony and Keynote
|
Presentation |
Start Time |
Presenter |
|---|---|---|
| Chairs' Welcome Address | 11:00 | Charles Rudin and Triparna Sen, Meeting Chairs |
| IASLC President Welcome | 11:05 | Heather Wakelee |
| IASLC Membership: Why We Should All be IASLC Members | 11:08 | Katie Maher |
| Remembrance for Pierre Massion | 11:11 | Johathan Lehman |
| Keynote: Lessons from CDX models in SCLC | 11:15 | Caroline Dive |
| Keynote Discussion with Q+A | 11:44 |
All Times in ET
Single Cell Analysis in SCLC
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Caroline Dive, Session Moderator | |
| Signatures of Plasticity, Metastasis, and Immunosuppression in a Single-cell Atlas of Human Small Cell Lung Cancer | 12:10 | Joseph Chan |
| Plasticity of SCLC Subtypes: Lessons from GEMMs | 12:22 | Trudy Oliver |
| Translating SCLC Molecular Subtypes into Clinical Practice: Opportunities for Precision Medicine and the Challenge of Plasticity | 12:35 | Lauren Byers |
| Single Cell Mass Cytometry and SCLC | 12:47 | Jonathan Lehman |
| Panel Discussion with Q&A | 13:00 |
All Times in ET
Omics in SCLC
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Trudy Oliver, Session Moderator | |
| Genomic Characterization of SCLC | 13:20 | Julie George |
| Systematic Determination of Functional Impacts of Recurrent SCLC Mutations | 13:32 | Dominic Rothwell |
| Recurrent WNT Pathway Alterations are Frequent in Relapsed Small-cell Lung Cancer | 13:44 | Siddhartha Devarakonda |
| Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation | 13:56 | Triparna Sen |
| Panel Discussion with Q&A | 14:08 |
All Times in ET
Biomarkers/Liquid Biopsy/Metastasis in SCLC
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Christine Lovly | |
| Small-cell Lung Cancer Brain Metastases Transcriptomics | 14:30 | Ata Abbas |
| Neddylation Inhibition as a Therapeutic Vulnerability in SCLC | 14:44 | David MacPherson |
| Molecular Profiling and Phenotype Mapping of SCLC Using Patient-derived Organoids | 14:58 | Hiroyuki Yasuda |
| SLFN11 in SCLC | 15:10 | Yves Pommier |
| Panel Discussion with Q&A | 15:23 |
All Times in ET
Novel Pathways and Targets in SCLC- Session 1
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Lauren Byers, Session Moderator | |
| Immunogenic Radiosensitization of SCLC with DNA Repair Inhibitors | 15:40 | Ben Lok |
| DLL3 | 15:52 | Katie Tully |
| LSD1-ZFP63L1 in SCLC | 16:04 | Matt Oser |
| Interactions between SCLC and Neurons | 16:16 | Humsa Venkatesh |
| Panel Discussion with Q&A | 16:28 |
All Times in ET
Clinical Trials in SCLC
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Kristin Higgins, Session Moderator | |
| Phase I/II Study of Olaparib and Temozolomide in SCLC: Updated Analysis | 16:50 | Catherine Meador |
| Clinical Trials in SCLC Immunotherapy | 17:03 | Luis Paz-Ares |
| Inflamed Subtype of SCLC and its Clinical Implications | 17:17 | Taofeek Owonikoko |
| Panel Discussion with Q&A | 17:30 |
All Times in ET
Closing
| Presentation | Start Time | Presenter |
|---|---|---|
| Day 1 Closing Message | 17:46 | Charles Rudin and Triparna Sen, Meeting Chairs |
All Times in ET
Satellite CME Symposium By PeerView:
Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?
18:05 - 19:05
Saturday, October 30, 2021
All Times in ET
Early Career Session (October 30)
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Ben Lok, Moderator | |
| MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate | 10:00 | Abbie Ireland |
| XPO1 as a Target for Chemoresistance in SCLC | 10:11 | Alvaro Quintanal Villalonga |
| Profiling of the cfDNA methylome for Detection and Subtyping of Small Cell Lung Cancers | 10:21 | Francesca Chemi |
| Targeting CDK7 to Enhance Immunity in SCLC | 10:32 | Hua Zhang |
| To Be or Not to B7-H6: Advancing Immunotherapy in Small Cell Lung Cancer | 10:44 | Portia Thomas |
| Molecular Subtyping of SCLC in Tumor Tissues and CTCs | 10:52 | Prasad Kopparapu |
| Panel Discussion with Q&A | 11:03 |
All Times in ET
Welcome and Keynote
| Presentation | Start Time | Presenter |
|---|---|---|
| Welcome | 11:30 | Charles Rudin and Triparna Sen, Meeting Chair |
| Keynote: Lessons from Mouse Models | 11:35 | Julien Sage |
| Keynote Discussion with Q&A | 11:58 |
All Times in ET
Subtypes/ Biomarkers in SCLC
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Jane Johnson, Session Moderator | |
|
Histological Subtyping of SCLC |
12:10 | Natasha Rekhtman |
|
SCLC Subgroups and Their Potential Clinical Significance |
12:24 |
Carl Gay |
| Whole Genome Methylation Analysis of Extensive Stage SCLC Samples Reveals Distinct Subtype-Specific Patterns | 12:34 | Simon Heeke |
| SCLC Biomarkers for Lung Cancer Screening | 12:47 | Samir Hanash |
| Panel Discussion with Q&A | 13:04 |
All Times in ET
Novel Pathways and Targets in SCLC - Session 2
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | JT Poirier, Session Moderator | |
| Therapeutic Targeting of ATR Yields Durable Regressions in High Replication Stress SCLCs | 13:20 | Anish Thomas |
| Molecular Subtypes of Primary SCLC Tumors and their Associations with Neuroendocrine and Therapeutic Markers | 13:36 | Haobin Chen |
| Guanosine Triphosphate Links MYC-dependent Metabolic and Ribosome Programs in Small-cell Lung Cancer | 13:48 | Ralph Deberardinis |
| Ferroptosis Response Segregates Small Cell Lung Cancer (SCLC) Neuroendocrine Subtypes | 14:00 | Silvia von Karstedt |
| Panel Discussion with Q&A | 14:12 |
All Times in ET
Mouse Models (Xenografts and GEMMs)
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Roman Thomas, Session Moderator | |
|
PBRM1 Functions as a Tumor Suppressor in Small Cell Lung Cancer |
14:30 | Arnaud Augert |
| Chemoresistance and co Clinical Trials | 14:43 | Ben Drapkin & Marcello Stanzione |
| Characterizing Chemoradiation Resistance in Small Cell Lung Cancer | 14:56 | Luigi Marchionni |
| Modeling Oncogenic & Histologic Transformation in the Lung | 15:10 | Eric Gardner |
| Panel Discussion with Q&A | 15:24 |
All Times in ET
Immunotherapy Approaches in SCLC
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Ticiana Leal, Session Moderator | |
| EZH2 and Plasticity of the Immune Response in SCLC | 15:40 | David Barbie |
| Harnessing the innate Immune System to Treat SCLC | 15:53 | Kate Sutherland |
| CDKs as Targets in Small Cell Lung Cancer | 16:06 | Kwok Kin Wong |
| Examining Predictors of Response to Immune Checkpoint Blockade in SCLC | 16:17 | Nitin Roper |
| Panel Discussion with Q&A | 16:28 |
All Times in ET
Day Two Closing
| Presentation | Start Time | Presenter |
|---|---|---|
| Closing Message | 16:50 | Charles Rudin and Triparna Sen, Meeting Chairs |
All Times in ET
| Presentation | Time |
|---|---|
| Industry Sponsored Symposium By Jazz Pharmaceuticals | 17:05 - 18:20 |
Thursday, October 28, 2021
CURE® is proud to host the second annual Lung Cancer Heroes® recognition event on Thursday, October 28, 2021 at 6:30 p.m. ET! Join us in honoring and expressing our heartfelt gratitude to this year’s honorees who have made a difference in the lung cancer community and continue to bring hope and healing to patients and their loved ones. CURE® is also pleased to announce that award-winning actress and filmmaker Laura Dern will be delivering this year’s keynote address! Please join us to make it an evening to remember.
Friday, October 29, 2021
All Times in ET
Opening Ceremony and Keynote
|
Presentation |
Start Time |
Presenter |
|---|---|---|
| Chairs' Welcome Address | 11:00 | Charles Rudin and Triparna Sen, Meeting Chairs |
| IASLC President Welcome | 11:05 | Heather Wakelee |
| IASLC Membership: Why We Should All be IASLC Members | 11:08 | Katie Maher |
| Remembrance for Pierre Massion | 11:11 | Johathan Lehman |
| Keynote: Lessons from CDX models in SCLC | 11:15 | Caroline Dive |
| Keynote Discussion with Q+A | 11:44 |
All Times in ET
Single Cell Analysis in SCLC
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Caroline Dive, Session Moderator | |
| Signatures of Plasticity, Metastasis, and Immunosuppression in a Single-cell Atlas of Human Small Cell Lung Cancer | 12:10 | Joseph Chan |
| Plasticity of SCLC Subtypes: Lessons from GEMMs | 12:22 | Trudy Oliver |
| Translating SCLC Molecular Subtypes into Clinical Practice: Opportunities for Precision Medicine and the Challenge of Plasticity | 12:35 | Lauren Byers |
| Single Cell Mass Cytometry and SCLC | 12:47 | Jonathan Lehman |
| Panel Discussion with Q&A | 13:00 |
All Times in ET
Omics in SCLC
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Trudy Oliver, Session Moderator | |
| Genomic Characterization of SCLC | 13:20 | Julie George |
| Systematic Determination of Functional Impacts of Recurrent SCLC Mutations | 13:32 | Dominic Rothwell |
| Recurrent WNT Pathway Alterations are Frequent in Relapsed Small-cell Lung Cancer | 13:44 | Siddhartha Devarakonda |
| Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation | 13:56 | Triparna Sen |
| Panel Discussion with Q&A | 14:08 |
All Times in ET
Biomarkers/Liquid Biopsy/Metastasis in SCLC
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Christine Lovly | |
| Small-cell Lung Cancer Brain Metastases Transcriptomics | 14:30 | Ata Abbas |
| Neddylation Inhibition as a Therapeutic Vulnerability in SCLC | 14:44 | David MacPherson |
| Molecular Profiling and Phenotype Mapping of SCLC Using Patient-derived Organoids | 14:58 | Hiroyuki Yasuda |
| SLFN11 in SCLC | 15:10 | Yves Pommier |
| Panel Discussion with Q&A | 15:23 |
All Times in ET
Novel Pathways and Targets in SCLC- Session 1
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Lauren Byers, Session Moderator | |
| Immunogenic Radiosensitization of SCLC with DNA Repair Inhibitors | 15:40 | Ben Lok |
| DLL3 | 15:52 | Katie Tully |
| LSD1-ZFP63L1 in SCLC | 16:04 | Matt Oser |
| Interactions between SCLC and Neurons | 16:16 | Humsa Venkatesh |
| Panel Discussion with Q&A | 16:28 |
All Times in ET
Clinical Trials in SCLC
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Kristin Higgins, Session Moderator | |
| Phase I/II Study of Olaparib and Temozolomide in SCLC: Updated Analysis | 16:50 | Catherine Meador |
| Clinical Trials in SCLC Immunotherapy | 17:03 | Luis Paz-Ares |
| Inflamed Subtype of SCLC and its Clinical Implications | 17:17 | Taofeek Owonikoko |
| Panel Discussion with Q&A | 17:30 |
All Times in ET
Closing
| Presentation | Start Time | Presenter |
|---|---|---|
| Day 1 Closing Message | 17:46 | Charles Rudin and Triparna Sen, Meeting Chairs |
All Times in ET
Satellite CME Symposium By PeerView:
Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?
18:05 - 19:05
Saturday, October 30, 2021
All Times in ET
Early Career Session (October 30)
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Ben Lok, Moderator | |
| MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate | 10:00 | Abbie Ireland |
| XPO1 as a Target for Chemoresistance in SCLC | 10:11 | Alvaro Quintanal Villalonga |
| Profiling of the cfDNA methylome for Detection and Subtyping of Small Cell Lung Cancers | 10:21 | Francesca Chemi |
| Targeting CDK7 to Enhance Immunity in SCLC | 10:32 | Hua Zhang |
| To Be or Not to B7-H6: Advancing Immunotherapy in Small Cell Lung Cancer | 10:44 | Portia Thomas |
| Molecular Subtyping of SCLC in Tumor Tissues and CTCs | 10:52 | Prasad Kopparapu |
| Panel Discussion with Q&A | 11:03 |
All Times in ET
Welcome and Keynote
| Presentation | Start Time | Presenter |
|---|---|---|
| Welcome | 11:30 | Charles Rudin and Triparna Sen, Meeting Chair |
| Keynote: Lessons from Mouse Models | 11:35 | Julien Sage |
| Keynote Discussion with Q&A | 11:58 |
All Times in ET
Subtypes/ Biomarkers in SCLC
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Jane Johnson, Session Moderator | |
|
Histological Subtyping of SCLC |
12:10 | Natasha Rekhtman |
|
SCLC Subgroups and Their Potential Clinical Significance |
12:24 |
Carl Gay |
| Whole Genome Methylation Analysis of Extensive Stage SCLC Samples Reveals Distinct Subtype-Specific Patterns | 12:34 | Simon Heeke |
| SCLC Biomarkers for Lung Cancer Screening | 12:47 | Samir Hanash |
| Panel Discussion with Q&A | 13:04 |
All Times in ET
Novel Pathways and Targets in SCLC - Session 2
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | JT Poirier, Session Moderator | |
| Therapeutic Targeting of ATR Yields Durable Regressions in High Replication Stress SCLCs | 13:20 | Anish Thomas |
| Molecular Subtypes of Primary SCLC Tumors and their Associations with Neuroendocrine and Therapeutic Markers | 13:36 | Haobin Chen |
| Guanosine Triphosphate Links MYC-dependent Metabolic and Ribosome Programs in Small-cell Lung Cancer | 13:48 | Ralph Deberardinis |
| Ferroptosis Response Segregates Small Cell Lung Cancer (SCLC) Neuroendocrine Subtypes | 14:00 | Silvia von Karstedt |
| Panel Discussion with Q&A | 14:12 |
All Times in ET
Mouse Models (Xenografts and GEMMs)
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Roman Thomas, Session Moderator | |
|
PBRM1 Functions as a Tumor Suppressor in Small Cell Lung Cancer |
14:30 | Arnaud Augert |
| Chemoresistance and co Clinical Trials | 14:43 | Ben Drapkin & Marcello Stanzione |
| Characterizing Chemoradiation Resistance in Small Cell Lung Cancer | 14:56 | Luigi Marchionni |
| Modeling Oncogenic & Histologic Transformation in the Lung | 15:10 | Eric Gardner |
| Panel Discussion with Q&A | 15:24 |
All Times in ET
Immunotherapy Approaches in SCLC
| Presentation | Start Time | Presenter |
|---|---|---|
| Session Welcome | Ticiana Leal, Session Moderator | |
| EZH2 and Plasticity of the Immune Response in SCLC | 15:40 | David Barbie |
| Harnessing the innate Immune System to Treat SCLC | 15:53 | Kate Sutherland |
| CDKs as Targets in Small Cell Lung Cancer | 16:06 | Kwok Kin Wong |
| Examining Predictors of Response to Immune Checkpoint Blockade in SCLC | 16:17 | Nitin Roper |
| Panel Discussion with Q&A | 16:28 |
All Times in ET
Day Two Closing
| Presentation | Start Time | Presenter |
|---|---|---|
| Closing Message | 16:50 | Charles Rudin and Triparna Sen, Meeting Chairs |
All Times in ET
| Presentation | Time |
|---|---|
| Industry Sponsored Symposium By Jazz Pharmaceuticals | 17:05 - 18:20 |
Message from Meeting Chair, Dr. Triparna Sen
Dr. Triparna Sen shares why you should join us for this year's IASLC Hot Topic Meeting: Small Cell Lung Cancer. From highlights on ongoing clinical trials to novel technologies in SCLC, it does not matter what area of SCLC research or treatment you are in, you will surely find a session that aligns to your discipline in the program.
Follow Us on Twitter
Share
Related Content
